Naturally Immune For Life

Autism Spectrum Disorder, the Gut Microbiome, and Immune Regulation

Over the past two decades, research has transformed our understanding of autism spectrum disorder (ASD). Once viewed primarily as a neurodevelopmental condition driven by genetics, ASD is now recognized as a complex disorder involving interactions between genetics, the immune system, the gut microbiome, and the brain. Mounting evidence indicates that alterations in the intestinal microbiota can influence immune development, neuroinflammation and behavior through the gut-brain axis. This growing body of research has opened new avenues for understanding ASD and has generated interest in microbiome-based therapies.

Early observations showed that gastrointestinal symptoms are common in children with ASD, affecting an estimated 30–70% of patients. Researchers also found that children with ASD frequently exhibit immune abnormalities, including elevated inflammatory cytokines, altered T-cell populations, and reduced immune regulation. These findings suggested that the immune system might serve as the biological bridge connecting the intestinal microbiome with the central nervous system. As studies progressed, investigators discovered that the composition of the gut microbiota differs significantly between individuals with ASD and neurotypical controls. Although results vary among studies, recurring patterns include increased abundances of Clostridium, Lactobacillus, and Faecalibacterium, together with reductions in Bifidobacterium, Enterococcus, and Streptococcus. These microbial shifts are thought to alter microbial metabolite production, intestinal barrier function, and immune signaling, all of which may influence brain development and behavior.

A major milestone came when researchers demonstrated that gut microbes could directly influence behavior. In groundbreaking fecal microbiota transfer experiments, gut microbiota collected from individuals with ASD were transplanted into germ-free mice. Remarkably, these recipient mice developed social deficits, repetitive behaviors, and other ASD-like characteristics despite having no genetic predisposition for autism. 

These experiments provided some of the strongest evidence to date that the gut microbiome itself contributes to disease rather than merely reflecting it. The findings also implicated microbial metabolites as important mediators of communication between the gut and the brain.

Building on these discoveries, a 2025 study published in Nature Communications provided one of the most detailed descriptions of the gut-immune-brain axis in autism. Using germ-free BTBR mice, a well-established mouse model of ASD, investigators found that the complete absence of intestinal microbes substantially improved several autism-associated behaviors, including repetitive behaviors, anxiety-like behavior, and impaired social memory. These behavioral improvements were accompanied by reduced activation of inflammatory CD4⁺ T cells within the brain and decreased neuroinflammation. Importantly, depletion of CD4⁺ T cells alone produced many of the same behavioral improvements, demonstrating that T-cell-mediated inflammation serves as a critical link between gut microbes and neurological function.

The investigators also identified microbial metabolites that may contribute to neurological dysfunction. Mice exhibiting ASD behaviors had elevated glutamate levels, an increased glutamate-to-GABA ratio, and increased concentrations of 3-hydroxyglutaric acid, a neurotoxic metabolite capable of disrupting excitatory and inhibitory neurotransmission. They further identified Limosilactobacillus murinus as a bacterium capable of promoting these metabolic changes and driving neuroinflammation. Conversely, administration of a selected Limosilactobacillus reuteri probiotic candidate reduced inflammatory responses, normalized neurotransmitter balance, lowered activation of brain-resident CD4⁺ T cells, and significantly improved ASD-associated behaviors. These findings suggest that carefully selected probiotic strains may eventually become adjunctive therapies capable of modifying disease mechanisms rather than simply treating symptoms.

Interest in probiotic therapy has therefore grown substantially. Several probiotic strains have demonstrated encouraging results in animal studies, including Limosilactobacillus reuteri ATCC PTA 6475, L. reuteri RC-14, and Bacteroides fragilis NCTC 9343. Early human clinical studies using L. reuteri ATCC PTA 6475 and DSM 17938 have also shown promise, although larger randomized clinical trials are still needed before firm conclusions can be drawn. As the prevalence of ASD continues to rise worldwide, identifying safe microbiome-directed interventions has become an important research priority.

Regulatory T cells

The role of regulatory T cells (Tregs) has also received increasing attention. These specialized immune cells maintain immune tolerance by suppressing excessive inflammatory responses and preventing inappropriate immune activation. In 2026, investigators at the UC Davis MIND Institute examined Tregs in children with ASD and found widespread abnormalities in both Treg phenotype and gene expression. Children with ASD exhibited altered expression of genes involved in immune signaling, metabolism, chromatin organization, and inflammatory regulation. Those with persistent gastrointestinal symptoms demonstrated particularly pronounced reductions in gut-homing activated Treg populations, suggesting impaired immune regulation within the intestinal environment. Lower Treg frequencies also correlated with more severe behavioral abnormalities, supporting the concept that defective immune regulation contributes to both gastrointestinal dysfunction and neurological symptoms in ASD.
Collectively, these studies support a unified model of ASD in which intestinal dysbiosis influences immune maturation, particularly CD4⁺ T cells and regulatory T cells, leading to chronic low-grade inflammation that extends beyond the gut and affects the brain. Microbial metabolites further influence neurotransmitter balance, microglial activation, and neuronal function, contributing to behavioral abnormalities. While the microbiome might not explain every case of autism, it has emerged as an important biological factor capable of modifying disease severity and potentially serving as a therapeutic target. Future treatments may combine dietary interventions, probiotics, prebiotics, postbiotics, and microbiome restoration strategies to support immune regulation and improve neurological function. Although much remains to be learned, the gut microbiome has become one of the most promising frontiers in autism research, providing new insights into how the immune system, intestinal microbes, and the brain function as an integrated biological network.

*Treg (Regulatory T cell) phenotype is the specific set of physical and molecular characteristics that define this specialized immune cell. Their primary role is to suppress immune responses, prevent autoimmunity, and maintain tolerance to harmless antigens.